Claudia Schroeder

Claudia Schroeder is an experienced clinical pharmacology professional currently serving as Clinical Pharmacology Lead at Boehringer Ingelheim since January 2024. Previously, Claudia held the position of Associate Director, Clinical Pharmacology at PTC Therapeutics, Inc., where responsibilities included the design and execution of Phase 1 studies related to rare diseases. From March 2012 to July 2022, Claudia led the clinical research team at Healix, Inc., overseeing outcomes and safety studies in various therapeutic areas, including Alzheimer's Disease and COVID-19. Prior roles include serving as a Clinical Research Pharmacist and a Consultant in Clinical Pharmacology, contributing to significant advancements in healthcare, including the development of omaveloxolone, the first treatment approved for Friedreich's ataxia. Claudia holds a PharmD and a PhD in Cancer Biology & Immunology from the Free University of Berlin.